Baxter International Inc.

• Persistent supply chain cost inflation caps operational margin turnaround well below normalized targets.
• Hospital procurement freezes or competitive tender losses push revenue into sustained contraction.
• Elevated debt carrying costs absorb operational cash flow, precluding organic balance sheet deleveraging.

A downside path develops if competitive pricing pressure from specialized peers forces gross margin concessions while high debt service burdens exhaust available cash flow. This outcome would be confirmed by gross margin erosion below documented operating floors and persistent annual operating losses.

Persistent operational delays failing to reverse negative operating income of -$308M under $9.67B in total debt compress valuation multiples below 2.2x.^4,5

• Consensus forward adjusted diluted earnings targets are achieved across FY2026 and FY2027.¹
• Operating margins expand steadily from negative territory toward normalized expectations.⁵
• International hospital procurement remains resilient across developed and emerging markets.⁶

Under the base path, Baxter delivers gradual operational improvements where operating margins normalize toward historical levels and international healthcare tenders sustain volume demand. Shares reach $26.92 with an estimated return of 18.1% at an assigned likelihood of 45.0%. Confirmation requires meeting forward consensus adjusted diluted earnings targets.¹

• Operating margin recovery accelerates toward broader medical technology industry benchmarks.
• Robust free cash flow generation accelerates balance sheet deleveraging without equity .